儿童急性淋巴细胞白血病严重毒性无生存(STFS)的医生定义
儿童急性淋巴细胞白血病5年总生存率已超90%,但幸存者面临永久健康后遗症,传统无事件生存不足以反映高治愈率下的严重持续并发症。17个国际研究组的儿童血液肿瘤专家发起倡议,构建严重毒性无生存(STFS)指标。通过五条通用纳入标准评估855种健康状况,经改良德尔菲法共识纳入21种严重毒性,旨在将医生优先关注的毒性整合到标准肿瘤结局报告中。
要点
- 儿童ALL 5年总生存率超90%,但幸存者存在永久健康后遗症,无事件生存指标不足。
- 17个国际ALL研究组专家构建STFS,以量化医生优先关注的严重毒性。
- 经改良德尔菲法共识纳入21种严重毒性,包括难治性癫痫、失明、心脏移植等。
核心结论
- STFS可量化儿童ALL治愈过程中临床上不可接受的健康代价,其严重毒性基于通用考量也适用于其他癌症诊断和年龄组。
研究设计与样本
- 由17个国际急性淋巴细胞白血病研究组代表的儿童血液肿瘤专家发起倡议,采用改良德尔菲流程辅以两次全体会议达成共识定义。
主要发现
- 采用五条通用纳入标准评估855种健康状况,最终纳入21种严重毒性。
- 21种严重毒性包括显著影响日常生活且治疗难治的严重不良健康状况(如难治性癫痫)、无治疗选择的状况(如失明)或需要重大侵入性治疗的状况(如心脏移植)。
关键数值与推荐
- 五条通用纳入标准:癌症诊断前不存在、有症状、可客观化、严重程度不可接受、永久性或需要不可接受的治疗。
- 评估了855种健康状况,纳入21种严重毒性。
临床怎么用
- 将STFS评估纳入临床试验,有望改善和多样化治疗策略,不仅关注传统结局事件和总生存,还关注最严重毒性的频率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff for cure using childhood acute lymphocytic leukaemia as a model disease, the prioritised severe toxicities are based on generic considerations of relevance to any other cancer diagnosis and age group.
引用
- Andrés-Jensen L, Attarbaschi A, Bardi E, et al. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Lancet Haematol. 2021. PMID: 34171282. doi:10.1016/S2352-3026(21)00136-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。